ithium Carbonate-COVID-19- mild and moderate -Exploratory / Phase II
- Conditions
- COVID-19SARS-CoV2BetacoronavirusCoronaviridae InfectionsCoronavirus InfectionsSARS Virus
- Registration Number
- RPCEC00000386
- Lead Sponsor
- Institute of Basic and Preclinical Sciences Victoria de Giron
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 192
1.Patient who expresses his consent to participate in the study in writing
2.Patients with positive RT-PCR
3.Age greater than or equal to 19 years
4.Mild or moderate symptomatic patients
1. Patients with decompensated chronic diseases (high blood pressure, diabetes mellitus, ischemic heart disease, chronic obstructive pulmonary disease, asthma, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmias, Addison's disease)
2. Patients with immunosuppression due to cancer, HIV or long-term treatment with immunosuppressants
3. Patients with chronic kidney failure
4. Patients with digestive autoimmune diseases (Crohn's disease, ulcerative colitis, among others) or thyroid
5. Pregnant or breastfeeding
6. Patients with treatments that deplete sodium or maintain a sodium restrictive diet
7. Patients with psychiatric illnesses or mental disabilities that prevent them from expressing their willingness to participate in the study or make its evaluation difficult
8. Patients hypersensitive to lithium
9. Lactose intolerant patients
10. Woman of childbearing age who does not use contraception and does not undertake to use it for at least one month after the end of the study treatment.
11. Patient participating in another clinical trial at the time of selection
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Erythrosedimentation (values in mm/h). Measurement time: Every 72 hours for a maximum of 15 days.
- Secondary Outcome Measures
Name Time Method